163 related articles for article (PubMed ID: 1760884)
21. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
23. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
24. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
25. Reference intervals for two bone-derived enzyme activities in serum: bone isoenzyme of alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TR-ACP).
Panteghini M; Pagani F
Clin Chem; 1989 Jan; 35(1):180-1. PubMed ID: 2910567
[No Abstract] [Full Text] [Related]
26. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
27. Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer.
Le Bricon T; Gay-Bellile C; Cottu P; Benlakehal M; Guillon H; Houzé P
J Clin Lab Anal; 2010; 24(1):20-4. PubMed ID: 20087950
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
Wada N; Fujisaki M; Ishii S; Ikeda T; Kitajima M
Breast Cancer; 2001; 8(2):131-7. PubMed ID: 11342986
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
[TBL] [Abstract][Full Text] [Related]
30. Biological variation in bone-derived biochemical markers in serum.
Panteghini M; Pagani F
Scand J Clin Lab Invest; 1995 Nov; 55(7):609-16. PubMed ID: 8633185
[TBL] [Abstract][Full Text] [Related]
31. Behavior of bone alkaline phosphatase (BAP) determined with immunoradiometric assay in metastatic prostate cancer.
Lorente JA; Morote J
Int J Biol Markers; 1994; 9(3):145. PubMed ID: 7530275
[No Abstract] [Full Text] [Related]
32. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
33. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
34. Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
Magnusson P; Larsson L; Englund G; Larsson B; Strang P; Selin-Sjögren L
Clin Chem; 1998 Aug; 44(8 Pt 1):1621-8. PubMed ID: 9702948
[TBL] [Abstract][Full Text] [Related]
35. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
36. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
Halleen JM
Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
[TBL] [Abstract][Full Text] [Related]
37. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
38. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
39. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer.
Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E
Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
